Praxis Precision Medicines Continues Trials on Essential Tremor Drug Despite Setbacks

In a recent development, Praxis Precision Medicines has announced its decision to proceed with two late-stage clinical trials of its drug ulixacaltamide, aimed at treating essential tremor, despite an interim analysis suggesting the drug’s potential inefficacy. The planned interim review indicated that ulixacaltamide was unlikely to meet the primary endpoints required for success in alleviating symptoms associated with essential tremor.

Despite these findings, Praxis remains committed to further investigating the drug’s effectiveness and will continue with the ongoing Phase 3 studies. Results from these continued trials are anticipated to be released in the third quarter of 2025.

This decision underscores Praxis Precision Medicines’ dedication to exploring all potential outcomes and contributing valuable data to the field of neurological treatment options. Further updates will be closely monitored by both medical professionals and stakeholders eagerly awaiting conclusive results later this year.

Date: March 3, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Breakthrough Study Suggests Common Antibiotic Vancomycin Could Treat Specific Inflammatory Bowel Disease Access to Free COVID-19 Tests in the United States A 3D Lung Model Raises the Bar for Research Breakthrough in Vitiligo Treatment: Microbial Therapy Shows Promising Results

Author

Mark Chiang

Ph.D in Biomedical Informatics Head of AI at GeneOnline